Tuesday | Wednesday | Thursday | Friday
WEDNESDAY, DECEMBER 8, 2021
     
All times are CENTRAL Time
 
7:00 am - 8:30 am CT POSTER SESSION 1 - Hall 1
 
7:00 am - 8:30 am CT  SPOTLIGHT POSTER DISCUSSION SESSIONS  

Spotlight Poster Discussion 1- Endocrine Resistance: Novel mechanisms and emerging new therapies - Stars at Night Ballroom 3&4

 
 

Chair: Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

New mechanistic insights to ER biology and endocrine therapies
Luca Magnani, PhD
Imperial College London
London, United Kingdom

Transcriptional reprogramming , ESR1 mutations, and novel targets and treatment
Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

 
 

Spotlight Poster Discussion 2 - Insights to CDK4/6i resistance: Novel models and clinical/translational genomics - Hall 4A

 
 

Chair: Richard Finn, MD
Geffen School of Medicine at UCLA
Los Angeles, CA

Are we closer to understanding why CDK 4/6 inhibitors stop working and what to do about it
Shom Goel, MD, PhD
Peter MacCallum Cancer Centre
Melbourne, Australia

Three CDK 4/6 inhibitors, a lot of biomarkers, what does it all mean moving forward?
Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

 
  Spotlight Poster Discussion 3 - Targets in Triple Negative Breast Cancer - Stars at Night Ballroom 1&2
 
 

Chair: Justin M. Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN

Immunotherapy/genomic implications
Clinton Yam, MD
UT MD Anderson Cancer Center
Houston, TX

Combined inhibition of CDK4/6 and AKT (LAR subtype)
Jennifer Richer, PhD
University of Colorado
Denver, CO

 
8:30 am - 11:15 am CT GENERAL SESSION 2 - Hall 3
 
8:30 am  GS2-00 Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer
Carey L, Solovieff N, André F, O'Shaughnessy J, Cameron DA, Janni W, Sonke GS, Yap Y-S, Yardley DA, Zarate JP, Taran T, Su F, Lteif A, Prat A. University of North Carolina, Chapel Hill, NC; Novartis Institutes for Biomedical Research, Cambridge, MA; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; Texas Oncology-Baylor University Medical Center and The US Oncology Research Network, Dallas, TX; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom; Department of Gynecology, University of Ulm, Ulm, Germany; Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, Netherlands; National Cancer Center Singapore, Singapore, Singapore; Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain. 
 
8:45 am GS2-01. Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer
O'Shaughnessy J, Stemmer SM, Burris HA, Yap Y-S, Sonke G, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga C, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, Hortobagyi GN. Texas Oncology-Baylor University Medical Center and The US Oncology Research Network, Dallas, TX; Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Sarah Cannon Research Institute, Nashville, TN; Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Medical Oncology, Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL; Department of Medical Oncology, Institut de Cancérologie de l’Ouest/René Gauducheau, Saint-Herblain, France; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Gynecology, University of Ulm, Ulm, Germany; Department of Surgery, Oncology and Gastroenterology and Division of Medical Oncology; University of Padua and Istituto Oncologico Veneto, IRCCS, Padua, Italy; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
 
     
9:00 am  GS2-02. Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
Bardia A, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier M-A, Sohn JH, Vuylsteke P, Harnden KK, Khong H, Kocsis J, Dalenc F, Kaklamani , Dillon P, Babu S, Waters S, Deleu I, García-Sáenz J, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortes J, Liu S, Laurent D, Conlan MG, Bidard F-C. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Universitaire Ziekenhuizen (UZ) - Leuven Cancer Institute, Leuven, BelgiumCentro Médico Austra, Buenos Aires, Argentina; University Hospitals Seidman Cancer Center- Case Western Reserve University, Cleveland, OH; Centre Hospitalier de l'Ardenne - Site de Libramont, Libramont-Chevigny, BelgiumCentre Jean Perrin, Clermont-Ferrand, FranceYonsei Cancer Center, Yonsei University Health System -Medical Oncology, Seoul, Republic of Korea; CHU UCL Namur – Site Sainte-Elisabeth, Namur, BelgiumInova Schar Cancer Institute, Fairfax, VA; Moffit Cancer Center & Research Institute, Tampa, FL; Bács-Kiskun Megyei Kórház, Kecskemét, HungaryInstitut Claudius Regaud, IUCT-Oncopole, Toulouse, FranceUniversity of Texas Health Sciences Center, Houston, TX; University of Virginia Cancer Center, Charlottesville, VA; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN; Velindre Cancer Centre, Cardiff, United KingdomAZ Nikolaas, Sint-Niklaas, BelgiumInstituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, SpainFondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, ItalyOspedale San Gerardo-ASST Monza, Monza, ItalyUniversity of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA; Institut Jules Bordet – Université Libre de Bruxelles, Brussels, BelgiumInternational Breast Cancer Center (IBCC), Quiron Group, Barcelona, SpainCytel, Waltham, MA; Berlin Chemie AG/Menarini Ricerche S.p.A, Berlin, GermanyRadius Health, Inc., Boston, MA; Institut Curie, Paris and Saint Cloud, France.
 
     
9:15 am  GS2-03. Discussant 
David W. Cescon, MD, PhD
Princess Margaret Cancer Centre
Toronto, Canada
 
     
9:30 am GS2-04. Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials
Bradley R, Braybrooke J, Gray R, Hills RK, Lui Z, Pan H, Peto R, Bergh J, Swain SM, Francis P, Gnant M, Perrone F, Regan MM. University of Oxford, Oxford, United Kingdom; Karolinska University Hospital, Solna, SwedenGeorgetown University Medical Center, Washington, WA; University of Melbourne, Melbourne, Australia; Medical University of Vienna, Vienna, Austria; National Cancer Institute of Naples, Naples, Italy; Dana-Farber Cancer Institute, Boston, MA.
 
     
9:45 am GS2-05. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials
Regan MM, Walley BA, Fleming GF, Francis PA, Colleoni MA, Láng I, Gómez HL, Tondini CA, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer, Jr, CE, Chini C, Minisini AM, Spazzapan S, Ruhstaller T, Winer EP, Ruepp B, Loi S, Coates AS, Goldhirsch A, Gelber RD, Pagani O. SOFT and TEXT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Groups, Bern, Switzerland.
 
     
10:00 am  GS2-06. Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials
Braybrooke J, Bradley R, Gray R, Hills R, Liu Z, Pan H, Peto R, Blum J, Chen X, Ejlertsen B, Janni W, Nitz U, Slamon D, Toi M, Watanabe T, Swain S, Bergh J, on behalf of the Early Breast Cancer Trialists Collaborative Group. University of Oxford, Oxford, United Kingdom; Baylor University Medical Centre, Dallas, TX; Shanghai Jiao Tong University, Shanghai, China; University of Copenhagen, Copenhagen, Denmark; University of Ulm, Ulm, GermanyWest German Study Group, Mönchengladbach, GermanyUniversity of California Los Angeles, Los Angeles, CA; Kyoto University, Kyoto, JapanHamamatsu Oncology Centre, Hamamatsu, JapanGeorgetown University Medical Center, Washington, DC; Karolinska University Hospital, Stockholm, Sweden.
 
     
10:15 am  GS2-07. Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)
Kalinsky KM, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LA, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga J-Y, Bermejo B, Ramos-Vasquez M, Jung KH, Ferrero J-M, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Pusztai L, Hortobagyi G. Emory University Winship Cancer Institute (SWOG), Atlanta, GA; SWOG Statistics and Data Management Center (SWOG), Seattle, WA; University of Washington School of Medicine/Seattle Cancer Care Alliance (SWOG), Seattle, WA; University of Texas MD Anderson Cancer Center (SWOG), Houston, TX; Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center (SWOG), Maywood, IL; Breast Oncology Program, Division of Hematology/Oncology, Department of Medicine, University of Michigan (SWOG), Ann Arbor, MI; Dana Farber Cancer Institute, Medical Oncology (Alliance for Clinical Trials in Oncology), Boston, MA; Mayo Clinic Jacksonville, Hematology/Oncology Division (Alliance for Clinical Trials in Oncology), Jacksonville, FL; Fox Chase Cancer Center (ECOG-ACRIN), Philadelphia, PA; British Columbia Cancer Agency, Medical Oncology (CCTG), Vancouver, BC, CanadaJuravinski Cancer Centre (CCTG), Hamilton, ON, Canada; Emory University Winship Cancer Institute (SWOG), University of Pittsburgh (NRG), PA; Hospital Clínico Virgen de la Victoria, UGCI Medical Oncology, IBIMA. GEICAM, Spanish Breast Cancer Group., Málaga, Spain; Institut Gustave Roussy (UNICANCER), Paris, France; Instituto de Investigación Sanitaria Gregorio Marañón, Department of Medical Oncology; Centro de Investigación Biomedica en Red de Oncologia, CIBERONC-ISCIII, sM Spanish Breast Cancer Group (GEICAM), Madrin, Spain; Mater Misericordiae University Hospital, Department of Medical Oncology; University College Dublin (Cancer Trials Ireland), Dublin, Ireland; Hospital Virgen del Rocío. GEICAM, Spanish Breast Cancer Group., Sevilla, Spain; L'Hospitalet de Llobregat, Medical Oncology. GEICAM, Spanish Breast Cancer Group, Barcelona, Spain; Instituto Nacional De Cancerologia (INCan), Mexico City, Mexico; Institut Curie (UNICANCER), Saint Cloud, France; National Cancer Center-Korea (NCC-Korea), Goyang-si Gyeonggi-do, Republic of Korea; Institut Curie Paris (UNICANCER), Paris, FranceHospital Clinico Universitario de Valencia; Biomedical Research Institute INCLIVA; Centro de Investigacion Biomedica en Red de Oncologia, CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group, Valencia, Spain; Centro Oncológico de Galicia. GEICAM Spanish Breast Cancer Group, A Coruña, Spain; University of Ulsan College of Medicine, Ulsan Medical Center (Korean Cancer Study Group), Seoul, Republic of Korea; Centre Antoine Lacassagne, Medical Oncology (UNICANCER), Nice, FranceGenomic Health/Exact Sciences, Redwood City, CA; University of Kansas Medical Center, Internal Medicine (SWOG), Kansas City, KS; Yale University (SWOG), New Haven, CT.
 
     
10:30 am  GS2-08. Discussant
Anne Blaes, MD
University of Minnesota
Minneapolis, MN
 
     
10:45 am GS2-09. Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations
Kubler K, Nardone A, Anand S, Gorvich D, Droog M, Hermida-Prado F, Akshi T, Feit AS, Cohen G, Dackus G, Pun M, Kuang Y, Cha J, Miller M, Gibson WJ, Paweletz CP, Van Allen EM, van Leeuwen FE, Nederlof P, Hollema H, Nguyen Q-D, Mourits MJE, Leshchiner I, Stewart C, Matulonis UA, Zwart W, Maruvka YE, Getz G, Jeselsohn R. Broad Institute, Cambridge, MA; Dana Farber Cancer Institute, Boston, MA; Technion, Haifa, Israel; Netherlands Cancer Institute, Amsterdam, Netherlands; University of Groningen, Groningen, Netherlands.
 
     
11:00 am  GS2-10. Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)
Barroso-Sousa R, Li T, Reddy S, Emens LA, Overmoyer B, Lange P, Dilullo MK, Attaya V, Kimmel J, Winer EP, Mittendorf EA, Tayob N, Tolaney SM. Hospital Sirio-Libanes, Brasília, Brazil; Dana-Farber Cancer Institute, Boston, MA; University of Texas Southwestern Medical Center, Houston, TX; University of Pittsburgh Medical Center, Pittsburgh, PA.
 
     
11:15 am Break  
     
10:00 am - 5:00 pm CT   EXHIBITS - Hall 2  
11:30 am - 12:00 pm CT WILLIAM L. MCGUIRE MEMORIAL LECTURE - Hall 3
Heterogeneity of Breast Cancer Genomes: Going Beyond Therapy to Risk Assessment and Prevention
Olufunmilayo (Funmi) Olopade, MD, FASCO, FACP, OON
University of Chicago Medicine
Chicago, IL
 
12:00 pm - 1:00 pm CT  CAREER DEVELOPMENT FORUM sponsored by Eisai, Inc. - Room 304  
  The Career Development Forum provides interactive informational interviews with experts on a variety of topics that are important for the career development of early-career scientists. The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2021 SABCS. In-person and virtual opportunities will be available for the Career Development Forum.

Attendance to the Virtual Career Development Forum will require pre-registration and will be limited to 60 participants. An invitation with a link to the pre-registration form will be sent to early-career scientists registered with a virtual registration ticket to the 2021 SABCS on Monday, November 22. The full program, including the participating mentors and list of breakout career topics, is available HERE.

Attendance to the in-person Career Development Forum will be limited to 120 participants on a first-come, first-served basis and limited to 120 participants. Pre-registration is not required, but badges are will be scanned at door for registration. Boxed lunches will be provided. Participants may visit as many or few tables during the session as they like. Some tables topics will have a more clinical focus, while others will have a more laboratory research focus. The subthemes are denoted in parenthesis after the table topic name.

In- Person CDF Schedule
12:00 pm ‐12:05 pm Introduction

12:05 pm -1:00 pm Rotation through roundtables (at leisure)

Roundtable Topics
12:05 ‐1:00 pm

1. Balancing Research and Clinical Practice (Clinical)

a. Cynthia Ma, Washington University Siteman Cancer Center, St. Louis, MO
b. Mentor to be announced
c. Jerri Francoeur, Alamo Breast Cancer Foundation, San Antonio, TX

2. Becoming a Successful Clinical Trialist (Clinical)

a. Carey Anders, Duke Comprehensive Cancer Center, Durham, NC
b. Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
c. Advocate to be announced

3. Careers in Industry

a. Oyewale Daejin Abidoye, Gilead Sciences Inc., Foster City, CA
b. Kim L. Blackwell, Tempus Labs, Indianapolis, IN
c. Amy C. Peterson, CytomX, South San Francisco, CA
d. Stacey Tinianov, Advocate Collaborative

4. Careers in Translational Research (Clinical)

a. Minetta C. Liu, Mayo Clinic College of Medicine and Science, Rochester, MN
b. Rita Nanda, University of Chicago, Chicago, IL
c. Janice Cowden, GRASP

5. Careers in Translational Research (Laboratory)

a. Justin M. Balko, Vanderbilt University, Nashville, TN
b. Mentor to be announced
c. Advocate to be announced

6. Making the Transition from Fellowship to Faculty (Clinical)

a. Dawn L. Hershman, Columbia University, New York, NY
b. Erica Stringer-Reasor, University of Alabama at Birmingham, Birmingham, AL
c. Advocate to be announced

7. Making the Transition from Fellowship to Faculty (Laboratory)

a. Fabrice André, Institut Gustave Roussy, Villejuif, France
b. Alana L. Welm, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
c. Abigail Johnson, Connect IV Legal Services, Inc.

8. Negotiating a Job Offer or Promotion

a. Norah Lynn Henry, University of Michigan, Ann Arbor, MI
b. Kevin Kalinsky, Emory Winship Cancer Center, Atlanta, GA
c. Jamie LaScala, Patient Advocate Board Member Translational Center of Excellence in Breast Cancer, Penn Medicine, Philadelphia, PA

9. How to Get Involved In & Make Collaborative Research Work for You

a. Angela M. DeMichele, University of Pennsylvania, Philadelphia, PA
b. Jorge Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, NY
c. Ginny Mason, Inflammatory Breast Cancer Research Foundation, West Lafayette, IN

10. Time Management to Optimize Productivity

a. Shelley Hwang, Duke Comprehensive Cancer Center, Durham, NC
b. Erika P. Hamilton, Sarah Cannon Research Institute, Nashville, TN
c. Bárbara Segarra-Vázquez, University of Puerto Rico, San Juan, PR

 
     
     
12:00 pm - 2:00 pm CT SPECIAL SESSIONS  
 

Re-framing Leadership in Academic Breast Oncology post COVID-19 - Hall 4A

Co-Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Co-Moderator: Rebecca Dent, MD
National Cancer Center Singapore
Singapore

Co-Moderator: Lisa Carey, MD, ScM, FASCO
University of North Carolina at Chapel Hill
Chapel Hill, NC

Learning by leading- lessons learned
Clifford A. Hudis, MD, FACP, FASCO
American Society of Clinical Oncology
Alexandria, VA

Building a successful translational breast cancer research program
Matthew J. Ellis, MB, BChir, BSc., PhD, FRCP
Lester and Sue Smith Breast Center
Baylor College of Medicine
Houston, TX

Panel Members:
Lisa A. Carey, MD, ScM, FASCO
University of North Carolina at Chapel Hill
Chapel Hill, NC

Charles M. Perou, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

 

Regulatory Insights to the 2021 Early Stage Breast Cancer Approvals - Stars at Night Ballroom 3&4
Moderator: Laleh Amiri Kordestani, MD
Food and Drug Administration
Silver Spring, MD

TBD
Christy Osgood, MD
Food and Drug Administration
Silver Spring, MD

TBD
Mirat Shah, MD
Food and Drug Administration
Silver Spring, MD

FDA approvals for early-stage breast cancer in 2021
Melanie Royce, MD
Food and Drug Administration
Silver Spring, MD

TBD
Alberto Montero, MD
University Hospitals Seidman Cancer Center
Cleveland, OH

 

Health Equity in Translational Research Studies - Stars at Night Ballroom 1&2
Co-Moderator: Melissa L. Bondy, PhD
Stanford Medicine
Stanford, CA

Co-Moderator: Patty Spears
University of North Carolina at Chapel Hill
Chapel Hill, NC

Working with patient advocates to promote diversity in trial participation and biospecimen donation
Vernal Branch
UNC Chapel Hill Breast SPORE
Chapel Hill, NC

Increasing accrual of Latinos into clinical trials: A cancer center’s perspective
Amelie Ramirez, DrPH
UT Health San Antonio
San Antonio, TX

Engaging racial and ethnic minority women in clinical trials and biospecimen donation: Keeping it simple, strategic, and sincere
Vanessa B. Sheppard, PhD
Virginia Commonwealth University
Richmond, VA

Integrating community networks in cancer research to increase diversity in clinical trials accrual
Lidia Schapira, MD, FASCO
Stanford University School of Medicine
Stanford, CA

Supporting and infusing health equity in translational research at the investigator and organizational level
Melissa Simon, MD, MPH
Northwestern University
Chicago, IL 

Panel Discussion

 
2:00 pm - 3:00 pm  CT TRANSLATIONAL SCIENCE FORUM  
 

ER Mutations and SERDS - Stars at Night Ballroom 3&4
Moderator: Fabrice Andre, MD, PhD
Institut Gustave Roussy
Villejuif, France

Next generation sequencing in ER targets
Donald P. McDonnell, PhD
Duke University School of Medicine
Durham, NC

ER+ word salad decoded: SERD, SERM, SERCA, CERAN, PROTAC
Komal Jhaveri, MD
Memorial Sloan Kettering Cancer Center
New York, NY

  BASIC SCIENCE FORUM  

Targeting Nuclear Steroid Receptors - Hall 4A
Moderator: Carol Lange, PhD
University of Minnesota
Minneapolis, MN

A new perspective on androgen receptor action in estrogen receptor-α positive breast cancer
Wayne Tilley, PhD
The University of Adelaide
Adelaide, Australia

PR
Christy R. Hagan, PhD
University of Kansas Medical Center
Kansas City, KS

GR
Suzanne Conzen, MD
UT Southwestern Medical Center
Dallas, TX

 

CASE DISCUSSIONS
 

Clinical Case Discussion - Stars at Night Ballroom 1&2
Moderator: Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN

Panel Members
Thelma Brown
Boon Chua
Hope Rugo
Anne Vincent-Solomon
Lee Wilke 

 


 
3:00 pm - 5:00 pm CT  EDUCATIONAL SESSIONS
 

Triple Negative Breast Cancer: Critical Update on Biology and Management - Stars at Night Ballroom 1&2
Moderator: Rita Nanda, MD
University of Chicago
Chicago, IL

Genomic and transcriptomic landscape of TNBC
Zhi-Ming Shao, MD
Fudan University of Shanghai
Shanghai, China

Optimizing the management of early stage TNBC
Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Brigham and Women's Cancer Center
Boston, MA

Management of special subtypes of TNBC
Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC

 

Emerging Adjuvant Therapies: What's Ready for Prime Time? - Stars at Night Ballroom 3&4
Moderator: Angela DeMichele, MSCE
University of Pennsylvania
Philadelphia, PA

Approving New Therapies for Early Breast Cancer
Suparna Wedam, MD
Food and Drug Administration
Silver Spring, MD

CDK4/6 for ER+
Ingrid A. Mayer, MD, MSCI
Vanderbilt-Ingram Cancer Center
Nashville, TN

IO vs Capecitabine for TNBC
Sherene Loi, MD, PhD
Peter MacCallum Cancer Centre
Melbourne, Australia

PARP for BRCA+ breast cancers
Andrew Tutt, MD
Institute of Cancer Research
London, United Kingdom

 

Fine Tuning Risk Assessment and Risk Reduction - Hall 4B
Moderator: Banu Arun, MD
UT MD Anderson Cancer Center
Houston, TX

Lifestyle: Exercise and diet
Neil M. Iyengar, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Emergent pharmacologic interventions for prevention: Non endocrine treatments
Brandy Heckman, PhD, MPH
National Cancer Institute
Rockville, MD

Imaging/AI
Constance Lehman, MD, PhD
Massachusetts General Hospital
Boston, MA

Panel Discussion
Ashley A. Dedmon

 

SABCS with the Society of Surgical Oncology present Local Therapy - Management of the Axilla - Hall 4A
Moderator: Hiram (Chip) Cody, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Axillary management in upfront surgery - staging, local control or both?
Stephanie Wong, MD, MPH
McGill University
Montreal, Canada

Refining axillary management after neoadjuvant chemotherapy - what does the evidence support
Eleftherios (Terry) Mamounas, MD, MPH, FACS
Orlando Health Cancer Institute
Orlando, FL

Can radiation replace ALND after + SLNB
Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

Options for reducing risk for lymphedema when ALND/regional nodal XRT are needed
Hani Sbitany, MD
Mount Sinai
New York, NY

 
5:00 pm - 6:30 pm CT POSTER SESSION 2 - Hall 1  
5:00 pm - 6:30 pm CT SPOTLIGHT POSTER DISCUSSIONS  

Spotlight Poster Discussion 4 - Brain Metastases: Managing LMD / Targeting HER2 - Stars at Night Ballroom 3&4
 
 

Chair: Andrew Brenner, MD
UT Health San Antonio
San Antonio, TX

Patricia Steeg, PhD
National Cancer Institute
Bethesda, MD

Eudocia Lee, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

 
  Spotlight Poster Discussion 5 -  Life After Breast Cancer: Cardiac Health, Fertility Preservation, and Returning to Life - Stars at Night Ballroom 1&2
 
 

Chair: Kathryn Ruddy, MD, MPH
Mayo Clinic
Rochester, MN

Cardiotoxicity
Carmen Bergom, MD, PhD
Washington University School of Medicine
St. Louis, MO 

Ovarian reserve and assisted reproduction
Maryam Lustberg, MD, MPH
Yale University School of Medicine
New Haven, CA

Employment changes, sedative hypnotic use, and risk of long-term chemotherapy toxicity
Tara Sanft, MD
Yale Cancer Center
New Haven, CT

 
  Spotlight Poster Discussion 6 - Genomic and Genetic Analysis on Metastases - Hall 4A
 
 

Chair: Christina Curtis, PhD, MSc
Stanford University
Stanford, CA

Christina Curtis, PhD MSc
Stanford University
Stanford, CA

Daniel Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH
 

 
7:00 pm - 9:00 pm CT

OPEN SATELLITE EVENT  - In-person Symposium will be held at the San Antonio Marriott Rivercenter hotel.

  What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast Cancer (Part 2 of a 3-Part CME Series) presented by Research To Practice
 
  Register for this complimentary in-person symposium or virtual event: http://www.researchtopractice.com/Meetings/SA2021  
     
7:30 pm - 9:30 pm CT OPEN SATELLITE EVENT  - In-person Symposia will be held at the San Antonio Marriott Rivercenter hotel.  
  Navigating the Evolving Treatment Landscape for ER-Positive Breast Cancer presented by Physicians’ Education Resource  
  Register for this complimentary in-person symposia or virtual event: HOME - Medical Crossfire®: Navigating the Evolving Treatment Landscape for HR-Positive Breast Cancer (gotoper.com)  
 
Tuesday | Wednesday | Thursday | Friday
 

S1-04.

S1-04.

Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Tuesday | Wednesday | Thursday | Friday